Aardvark Therapeutics (NASDAQ:AARD) Releases Quarterly Earnings Results, Beats Estimates By $0.21 EPS

Aardvark Therapeutics (NASDAQ:AARD) posted its earnings results on Tuesday. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.21, Zacks reports.

Aardvark Therapeutics Trading Down 1.0%

AARD stock opened at $7.12 on Wednesday. The stock has a market capitalization of $155.70 million, a PE ratio of -2.24 and a beta of 3.81. Aardvark Therapeutics has a 12-month low of $3.35 and a 12-month high of $17.94. The stock’s 50 day simple moving average is $5.49 and its 200 day simple moving average is $6.61.

Analysts Set New Price Targets

A number of research analysts have issued reports on AARD shares. BTIG Research downgraded shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. HC Wainwright reaffirmed a “neutral” rating and set a $6.00 target price on shares of Aardvark Therapeutics in a research note on Monday, July 20th. B. Riley Financial lowered their price objective on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Friday, May 15th. Weiss Ratings raised Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 2nd. Finally, Morgan Stanley reissued an “underweight” rating and set a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a research report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Aardvark Therapeutics has a consensus rating of “Hold” and an average target price of $16.30.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Citadel Advisors LLC boosted its position in shares of Aardvark Therapeutics by 5.9% during the third quarter. Citadel Advisors LLC now owns 1,359,883 shares of the company’s stock valued at $18,073,000 after buying an additional 76,151 shares during the last quarter. Laurion Capital Management LP raised its position in Aardvark Therapeutics by 6.1% in the 3rd quarter. Laurion Capital Management LP now owns 1,049,721 shares of the company’s stock worth $13,951,000 after buying an additional 60,653 shares during the last quarter. Vanguard Group Inc. raised its position in Aardvark Therapeutics by 20.6% in the 3rd quarter. Vanguard Group Inc. now owns 555,721 shares of the company’s stock worth $7,386,000 after buying an additional 94,744 shares during the last quarter. Millennium Management LLC lifted its stake in Aardvark Therapeutics by 51.2% during the 4th quarter. Millennium Management LLC now owns 483,340 shares of the company’s stock valued at $6,344,000 after acquiring an additional 163,717 shares during the period. Finally, SymBiosis Capital Partners LLC bought a new position in Aardvark Therapeutics during the 4th quarter valued at about $6,255,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.